Takeda Expands Oncology Pipeline With Cell Therapy Startup Buyout

Takeda Pharmaceutical Company Limited TAK announced the exercise of its option to acquire GammaDelta Therapeutics Limited, a T cell startup.
A little more than four years ago, Takeda stepped in to help bankroll GammaDelta Therapeutics with a $100 million injection.
Takeda will obtain GammaDelta's allogeneic variable delta 1 (Vδ1) gamma-delta (γδ) T cell therapy platforms, including both blood-derived and tissue-derived platforms, in addition to early-stage cell therapy programs.
Financial terms were not available.
The acquisition follows a multi-year collaboration between Takeda and GammaDelta formed in 2017 to develop GammaDelta's novel γδ T cell therapy platforms.
Takeda received an equity stake and an exclusive right to purchase GammaDelta.
The deal is expected to be finalized in Q1 of Takeda's fiscal year 2022.
Price Action: TAK shares are down 0.11% at $13.84 during the market session on the last check Wednesday.